We’re excited to continue to grow our executive team and welcome Scott Akamine to Kailera as Chief Legal Officer! Scott is an accomplished legal executive with significant healthcare and biopharmaceutical experience, and we’re thrilled to have him on board. Welcome, Scott! https://lnkd.in/e7VUXZeY #KaiCrew #KaileraTx
Kailera Therapeutics
生物技术研究
Developing therapies for obesity and related conditions to empower people to transform their lives.
关于我们
Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2024
Kailera Therapeutics员工
动态
-
At?Kailera Therapeutics, we are bold, authentic, and driven by our mission to develop therapies that empower people to transform their lives and elevate their overall health. Rooted in a spirit of entrepreneurship and collaboration, we are advancing innovative treatments for obesity and related conditions. ? As we continue to grow, we’re looking for talented individuals with diverse backgrounds, perspectives, and experiences to join our dynamic team.?We are currently hiring in?clinical development, technical operations and medical affairs.? ? Ready to make an impact??Explore our open roles to join?the #KaiCrew on our mission! https://lnkd.in/eHaMf8E3 ? #Careers #Hiring #Biotech #KaileraTx
-
Our launch was featured on the Nasdaq Tower in Times Square today!?Thank you Nasdaq for showcasing our announcement in such an iconic, memorable way. We’re grateful to launch Kailera with such tremendous support and momentum! #KaileraTx
-
-
Introducing Kailera Therapeutics-- a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. Launching today with our $400 million Series A financing co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, LP, with participation from Lyra Capital, we are developing several clinical-stage injectable and oral therapies that demonstrated potential as best-in-class treatments for chronic weight management. In conjunction with our launch, we are thrilled to announce our initial executive leadership team appointments including: Ron Renaud, Chief Executive Officer Doug Bakan, Ph.D., Chief Technology Officer Paul Burgess, Chief Operating Officer and Chief Business Officer Paula Cloghessy, SPHR, SHRM-SCP, Chief People Officer Scott Wasserman, M.D., Chief Medical Officer Additionally, we are excited to welcome industry veteran John F. Milligan, Ph.D., as our Board Chair. Our leadership team and board of directors have deep industry experience and a track record of building successful companies, positioning Kailera to advance innovative therapies with the potential to meaningfully impact both quality of life and overall health for many people. Thank you to our dedicated team, board, and investors for supporting our mission to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health! Learn more: https://lnkd.in/eRSBh7yX